
Bruno Bockorny, MD, discusses the phase 1 C-800 trial of botensilimab plus bastilimab, specifically for patients in the C-800-01 cohort with recurrent platinum refractory/resistant ovarian cancer.

Your AI-Trained Oncology Knowledge Connection!

Bruno B. Bockorny, MD is affiliated with Beth Israel Deaconess and specializes in Hematology and Medical Oncology in Boston, MA.

Bruno Bockorny, MD, discusses the phase 1 C-800 trial of botensilimab plus bastilimab, specifically for patients in the C-800-01 cohort with recurrent platinum refractory/resistant ovarian cancer.

Bruno Bockorny, MD, explains the mechanism of action of botensilimab and its use in combination with balstilimab for ovarian cancer treatment.